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a  b  s  t  r  a  c  t
Background:  Although  tolvaptan  is  a  recently  approved  drug  for heart  failure  and  causes  aquaresis  without
affecting  renal  function,  its  clinical  efﬁcacy  for patients  with  acute  decompensated  heart  failure  (ADHF)
is  yet  to  be elucidated.
Methods and  results:  We  conducted  a prospective  observational  study  in  patients  with  ADHF  and  high
risk  for  worsening  renal  function  (WRF).  Risk  stratiﬁcation  for WRF  was  done  by  scoring  system.  Of  174
patients,  114  patients  were  included  as  high-risk  population  for  WRF.  Incidence  of  WRF,  urine  output
within  24  h  and  48  h,  and  changes  in  brain  natriuretic  peptide  (BNP)  were  recorded  in  44  patients  treated
with  tolvaptan  plus  conventional  therapy,  and  70  patients  with  only  conventional  therapy.  Urine  output  at
24 h and  48 h after  admission  were  both  signiﬁcantly  higher  in  the tolvaptan  group  (p  =  0.001  and  <0.001,
respectively),  and  changes  in  BNP  were  not  signiﬁcantly  different  (p  =  0.351).  However,  the  incidence  of
WRF was  signiﬁcantly  lower  in  the tolvaptan  group  compared  to  the  conventional  group  (22.7%  vs  41.4%,
p = 0.045).  Logistic  regression  analysis  showed  that treatment  with  tolvaptan  was an  independent  factor
for  reducing  WRF  (hazard  ratio  0.28,  95%  conﬁdence  interval;  0.10–0.84;  p = 0.023).
Conclusion:  In patients  with  ADHF  with  high  risk  of  WRF,  treatment  with  tolvaptan  could  prevent  WRF
compared  to  conventional  therapy.
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Acute decompensated heart failure (ADHF) is one of the leading
auses of hospital admission in the whole world. Despite signiﬁ-
ant advances in pharmacologic and device therapy that have led
o improved outcome for patients with chronic heart failure, an
nmet need exists for a more effective and safe strategy to treat
DHF. The primary aim of therapy for ADHF is reduction of the
ongestive state with salt and water removal, and diuretics are
he mainstay of primary therapy in ADHF. Although this strategy
s effective in the acute care setting, diuretics therapy has been
ssociated with adverse effects, including electrolyte abnormality,
eurohormonal activation, and renal dysfunction, so called, wors-
ning of renal function (WRF) [1].
Recently, some studies have shown that renal function is one
f the strong factors that contribute to prognosis of heart failure
2–5]. WRF  coexisting with ADHF is a common situation, and this
omplicates the treatment course of heart failure [6],  because WRF
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leads to diuretics refractoriness [7],  longer length of hospital stay
[8],  and increase in mortality and additional hospitalizations during
follow-up [2,9,10]. Although some risk factors for WRF  were identi-
ﬁed [11], there are few therapeutic strategies speciﬁed for patients
with ADHF and WRF.
Tolvaptan is an oral selective V2 receptor antagonist which acts
on the distal nephron and causes loss of electrolyte-free water. This
is a promising drug because some studies have shown the prefer-
able effects for renal function with tolvaptan when it is used in
heart failure patients [1,12,13]. We,  therefore, hypothesized that




We  prospectively included patients admitted with a diagnosis
of ADHF and who were predicted as being at high risk of WRF
between January 2011 and September 2011. Prediction of WRF  was
performed according to a scoring system which was reported by
Forman et al. [14], and patients with a risk score greater than or
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qual to three were classiﬁed as high-risk population for WRF. The
ttending physician diagnosed heart failure according to the Fra-
ingham criteria [15]. Patients with acute myocardial infarction,
ardiogenic shock, patients who required inotropic agents, or who
ad valvular disease, myocarditis, hypertrophic cardiomyopathy,
nd Takotsubo cardiomyopathy were excluded. We  also excluded
atients with severe renal impairment (estimated glomerular ﬁl-
ration rate < 15 mL  kg−1 1.73−2) at admission, because prompt
ltraﬁltration was necessary to stabilize the vital signs. All patients
ave their written informed consent, and the study was approved
y the local ethics committee.
The patients who were included in the present study were
ivided into two  groups according to the use of tolvaptan 15 mg
nce daily with conventional therapy, including diuretics, digoxin,
asodilators, or not. Choice of therapies was at the discretion of the
reating physician.
coring system of WRF
In our investigation, we used the risk scoring system which
as proposed by Forman et al. [14]. This analysis yielded a
coring system where 1 point each was assigned to history
f heart failure, history of diabetes, and systolic blood pres-
ure > 160 mmHg  at baseline; 2 points were assigned to plasma
reatinine 1.5–2.4 mg/dL; and 3 points were assigned to plasma
reatinine ≥ 2.5 mg/dL. According to this score, groups of patients
ith a risk score 2 had approximately double the risk of develop-
ng WRF, groups of patients with a risk score 3 had approximately
riple the risk of developing WRF  and patients with a risk score 4
r more had >5 times the risk when compared with patients with
 risk score of 0. We,  therefore, considered the patients with risk
core greater than or equal to two as high-risk population for WRF.
ata collection
All data were collected prospectively. Laboratory data included
rine output, serum creatinine, serum concentrations of sodium,
otassium, brain-type natriuretic peptide (BNP) were obtained at
aseline, 24 h, and 48 h after starting treatment for ADHF. Patients
ho were taking antihypertensive agents were considered to have
ypertension. Hypercholesterolemia was deﬁned as serum total
holesterol level ≥ 220 mg/dL or the requirement of treatment with
ipid-lowering agents. Patients were considered smokers if they
ere current smokers. Diabetes mellitus was diagnosed according
o the World Health Organization (WHO) criteria [16], or if taking
nti diabetic drugs. Estimated glomerular ﬁltration rate (eGFR) was
alculated by using Modiﬁcation of Diet in Renal Disease (MDRD)
tudy equation coefﬁcients modiﬁed for Japanese [17].
utcomes measurements
The primary endpoint of this study was incidence of WRF
deﬁned as serum creatinine elevation of 0.3 mg/dL or 50% above
aseline within 48 h [18]). The secondary endpoints were cumu-
ative urine output at 24 h and 48 h after admission, dose of
urosemide used within 48 h after admission, and changing rate
f BNP from baseline.
tatistical analysis
All continuous data are expressed as means ± standard devia-
ion and the mean differences between groups were analyzed using
tudent’s t-test or analysis of variance (ANOVA). Proportional dif-
erences were analyzed using the Fisher exact analysis. Categorical
ariables were analyzed using the chi-squared test. We  calculated
azard ratios (HRs) derived from the logistic regression modeliology 61 (2013) 169–174
to evaluate the contribution of each factor for WRF. All baseline
variables, including echocardiographic parameters, were included
in the logistic regression analyses. Multivariate analysis was per-
formed using all variables with p < 0.1 on univariate analysis. A
p-value of less than 0.05 was considered statistically signiﬁcant.
Data analysis was performed with SPSS 19.0 statistical software
(SPSS Inc., Chicago, IL, USA).
Results
Incidence of WRF  and risk score
During the study period, a total of 176 admitted ADHF patients
were included, and risk score for WRF  was  calculated as the arith-
metic sum of point values assigned to each independent predictor,
as described above. The number of patients with each score and
relationship between each risk score and the incidence of WRF  is
shown in Fig. 1. As shown, patients with higher risk score were
more likely to develop WRF  – 64.7% of all subjects had a risk score
equal to or more than 2, and this population had 34.2% likelihood
of developing WRF  compared to only 16.1% among the population
with a risk score less than 2 (p < 0.01).
After risk stratiﬁcation with this score, we included 114 patients
with risk score equal to or above 2 to investigate the efﬁcacy of
tolvaptan. Baseline patient characteristics are listed in Table 1.
Of these patients, 44 were treated with tolvaptan (tolvaptan
group), and others were treated with conventional therapy (con-
ventional group). There were some signiﬁcant differences between
the tolvaptan group and the conventional group. The patients in
the tolvaptan group had higher blood pressure, higher serum cre-
atinine, lower eGFR, higher BNP level, higher rate of history of heart
failure, less treatment with vasodilators, and higher risk score of
WRF.
Clinical efﬁcacy of tolvaptan
Table 2 indicates the clinical course of patients. In the tolvaptan
group, signiﬁcantly more cumulative urine output at both 24 h and
48 h was  achieved compared to the conventional group (p = 0.001,
and p < 0.001, respectively). The dose of furosemide which was  used
within 48 h tended to be less in the tolvaptan group, however, the
difference was not statistically signiﬁcant. The rate of BNP reduc-
tion also did not show a signiﬁcant difference. The incidence of WRF
was signiﬁcantly lower in the tolvaptan group compared to the con-
ventional group (22.7% and 41.4%, respectively; p = 0.045) (Fig. 2),
despite achieving more urine output. There was  no patient who
had to withdraw from administration of tolvaptan due to adverse
events within 48 h.
Multivariate analysis for WRF
As there were some signiﬁcant differences in the baseline
patient characteristics between the tolvaptan group and the con-
ventional group, we performed logistic regression analysis. On
univariate analysis, history of heart failure, serum creatinine, serum
value of sodium, and hemoglobin at admission, and treatment
without tolvaptan were associated with higher risks of WRF. After
adjusted multivariate Cox regression analysis, including all vari-
ables with p < 0.1 on univariate analysis, history of heart failure (HR
3.16, 95% CI 1.16–8.60; p = 0.025), serum creatinine at admission
(HR 3.08, 95% CI 1.45–6.54; p = 0.004), and treatment with tolvaptan
(HR 0.28, 95% CI 0.10–0.84; p = 0.023) were signiﬁcantly associated
with occurrence of WRF  (Table 3).
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Fig. 1. Number of patients and the incidence of WRF  for each score. The red bar indicates the number of patients with WRF, and blue bar indicate without WRF. The numbers
above each bar indicate rate of WRF  for each scored patient. WRF, worsening of renal function.
Table 1
Baseline clinical characteristics of tolvaptan group and conventional group.
Characteristics Tolvaptan group (n = 44) Conventional group (n = 70) p-Value
Age (years) 72.2 ± 11.8 70.8 ± 10.5 0.487
Male  (%) 18 (51.4) 2 (22.2) 0.238
BMI  24.4 ± 2.8 24.9 ± 2.8 0.967
Smoking (%) 15 (34.1) 32 (45.7) 0.315
HF  ischemic etiology (%) 14 (31.8) 23 (32.9) 0.538
NYHA  class IV 17 (38.6) 33 (47.1) 0.207
Systolic blood pressure (mmHg) 121.8 ± 23.6 140.3 ± 33.8 0.002
Diastolic blood pressure (mmHg) 66.8 ± 16.1 76.0 ± 19.3 0.010
Heart  rate (bpm) 87.4 ± 21.9 85.0 ± 32.4 0.669
LVEF  (%) 46.4 ± 16.1 50.5 ± 14.6 0.162
LVEF  < 50% (%) 28 (74.6) 35 (50.0) 0.109
End-diastolic diameter (mm)  55.1 ± 9.8 55.0 ± 8.4 0.944
End-systolic diameter (mm)  42.0 ± 12.3 41.0 ± 10.4 0.634
LAD  (mm) 45.5 ± 8.8 48.5 ± 8.5 0.076
Medical history
Hypertension (%) 33 (75.0) 48 (68.6) 0.302
Diabetes mellitus (%) 24 (54.5) 50 (73.5) 0.031
Heart  failure (%) 32 (81.8) 43 (61.4) 0.017
Dyslipidemia (%) 18 (40.9) 31 (44.3) 0.437
Cerebral infarction (%) 6 (13.6) 7 (10.0) 0.379
Atrial  ﬁbrillation (%) 25 (56.8) 42 (60.0) 0.815
Medications at admission
Aspirin 16 (36.4) 26 (37.7) 0.525
ACE-I/ARB 31 (70.5) 43 (61.4) 0.218
Beta  blocker 23 (52.3) 30 (42.9) 0.215
Statin  17 (38.6) 26 (37.1) 0.514
CCB  18 (40.9) 33 (47.1) 0.324
Diuretics 36 (81.8) 50 (71.4) 0.266
Dose  of furosemide 33.4 ± 20.9 27.3 ± 22.2 0.145
Spironolactone 21 (47.7) 32 (45.7) 0.493
Vasodilators in acute phase (%) 8 (18.2) 29 (41.4) 0.013
Data  at admission
Serum creatinine (mg/dL) 1.94 ± 1.06 1.43 ± 0.58 0.001
eGFR  (mL/min/1.73 m2) 35.0 ± 23.7 46.4 ± 23.8 0.035
Hemoglobin (g/dL) 12.4 ± 2.0 12.5 ± 2.7 0.788
Sodium (mEq/L) 136.6 ± 8.2 139.5 ± 3.9 0.191
BNP  (pg/dL) 1138.9 ± 651.9 792.7 ± 571.4 0.004
Total  cholesterol 152.8 ± 46.4 165.3 ± 51.4 0.191
LDL  cholesterol 87.3 ± 40.5 97.1 ± 44.7 0.241
HbA1c (%) 6.0 ± 0.7 6.1 ± 0.8 0.393
WRF  predict score 3.1 ± 0.8 2.8 ± 0.8 0.049
Data given as n (%) or mean ± SD.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CCB, calcium channel blocker;
eGFR,  estimated glomerular ﬁltration rate; HbA1c, hemoglobin A1c; HF, heart failure; LAD, left atrium diameter; LDL, low-density lipoprotein; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association; WRF, worsening of renal function.
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Table 2
Clinical course of tolvaptan group and conventional group.
Tolvaptan group (n = 44) Conventional group (n = 70) p-Value
0–24 h urine output (mL) 3122 ± 1895 2250 ± 900 0.001
0–48  h urine output (mL) 6187 ± 3401 4398 ± 1323 <0.001
Dose  of furosemide for 48 h (mg) 71.5 ± 51.2 91.0 ± 44.4 0.105
Changes in BNP (%) −30.6 ± 37.5 −37.6 ± 39.3 0.351
BNP, brain natriuretic peptide.
Table 3
Univariate and multivariate predictors of WRF.
Variable Univariate Multivariate
HR (95% CI) p-Value HR (95% CI) p-Value
Medical history
Heart failure (%) 2.44 (1.07–5.59) 0.034 3.16 (1.16–8.60) 0.025
Data  at admission
Serum creatinine (mg/dL) 2.23 (1.23–3.98) 0.006 3.08 (1.45–6.54) 0.004
Hemoglobin (g/dL) 0.78 (0.66–0.94) 0.007 0.78 (0.67–1.02) 0.078
Sodium (mEq/L) 1.08 (0.99–1.18) 0.078 1.07 (0.97–1.18) 0.200
Tolvaptan group 0.42 (0.18–0.97) 






















[ig. 2. The incidence of WRF  in the tolvaptan group and conventional therapy group.
RF, worsening of renal function.
iscussion
The most important ﬁnding of the present study was that tolvap-
an could achieve more diuresis without WRF  in patients at high
isk for WRF. Moreover, hypernatremia, which was deﬁned as rise
n serum concentration of sodium more than 12 mEq/L within 48 h
rom administration of tolvaptan, did not occur. It means that
olvaptan is safe and effective for patients with patients with ADHF
nd renal failure.
iuretic effect of tolvaptan
In patients with ADHF, initial therapy focuses on sodium and
uid restriction and removal. At present, diuretics are the main-
tay of therapy in ADHF to reduce volume overload that results in
ongestion. Although loop diuretics result in prompt diuresis and
elief of symptoms in most patients, some study has shown that
oop diuretics activate the renin–angiotensin–aldosterone system
RAAS) and the sympathetic nervous system, both of which are
nown to play a fundamental role in ADHF [19–21].  In another
eport, administration of loop diuretics to patients with heart
ailure may  be associated with an increase in systemic vascu-
ar resistance and may  initially raise ventricular ﬁlling pressures.
lthough loop diuretics are used as foundation therapy in ADHF
22], the data that show safety and efﬁcacy of loop diuretics in0.043 0.28 (0.10–0.84) 0.023
h p < 0.1 on univariate analysis were included in the multivariate model.
ADHF are sparse. Indeed, the ADHERE registry has suggested that
there may  be adverse effects from treatment with intravenous loop
diuretics in patients who  present with ADHF [23].
Tolvaptan is an oral nonpeptide vasopressin V2 receptor antag-
onist that blocks the effect of arginine vasopressin (AVP) on renal
collecting tubes, resulting in aquaresis and resolution of hypona-
tremia. In our study cohort, tolvaptan achieved signiﬁcantly more
diuresis with lower doses of furosemide in the acute phase of
ADHF without WRF, and this may  suggest that using tolvaptan
could decrease the dose of furosemide. Moreover, the degree of
decreasing BNP was not signiﬁcantly different between furosemide
and tolvaptan, and this may  suggest that clinical efﬁcacy of tolvap-
tan was  not inferior to conventional therapy with furosemide.
In patients with ADHF and renal failure, diuretics refractori-
ness is one of the factors that complicates treatment course of
ADHF, because the diuretic effect of diuretics seems to be mostly
inﬂuenced by renal function [24]. Also reduced renal blood ﬂow
further inhibits tubular delivery of the diuretics [7].  In the present
study, the average value of eGFR at admission of all subjects
who were included as high-risk population was  extremely low
(39.8 mL/min/1.73 m2, data not shown), and this may  be the reason
why signiﬁcant difference were shown in urine output between
tolvaptan and furosemide in the acute phase. In addition, some
studies have shown that RAAS activity, which is provoked by loop
diuretics, is one of the contributing factors for diuretic resistance
[25,26]. On the other hand, tolvaptan has been shown to not acti-
vate RAAS, and this may  be one reason why more diuresis was
achieved with tolvaptan.
WRF  in ADHF
Several studies have shown that between 27% and 40% of
patients who were admitted due to ADHF experience some increase
in creatinine, so called WRF, and these patients suffer from higher
mortality and morbidity, increased length of hospitalization [27],
accelerated progression to chronic kidney disease stages 4–5 [28],
and higher healthcare costs [29]. In addition, two other studies
have also shown that the risk of poor outcome persists regardless
of whether WRF  was  transient or sustained, and even small acute
changes in serum concentration of creatinine (0.3 mg/dL) can mod-
ify the risk of death [30,31]. In present study, we performed risk
stratiﬁcation with WRF  predicting score. As shown in the results,
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RF, and this indicates the validity of WRF  prediction score for our
ohort.
In some studies, the favorable effects for renal function of
olvaptan were reported both in in vitro and in vivo investigations.
iyazaki et al. have shown that tolvaptan induced aquaresis with-
ut compromising renal function, activating sympathetic nerve
ystem and RAAS compared to furosemide in a canine model of
eart failure [32]. In an open-label, randomized placebo-controlled
rossover trial, Costello-Boerrigter et al. reported that tolvaptan
ause aquaresis without decreasing renal blood ﬂow, and increas-
ng plasma renin activity and serum aldosterone, both components
f the RAAS in patients with heart failure [33]. In the present study,
e showed that the incidence of WRF  was signiﬁcantly lower in
atients who were treated with tolvaptan compared to patients
ho were treated with conventional therapy, despite the fact that
ore urine output was achieved in the tolvaptan group. This may
ndicate the safety and effectiveness of tolvaptan even in patients
ith ADHF and renal failure.
The Efﬁcacy of Vasopressin Antagonism in Heart Failure Out-
ome Study with Tolvaptan (EVEREST) trial did not show a
igniﬁcant improvement in two primary endpoints of all-cause
ortality and cardiovascular death or hospitalization for heart
ailure, with a median follow-up of 9.9 months, despite more
mprovements in symptoms and body weight in acute phase [34].
oreover, the incidence of WRF  was not different between the
olvaptan group and placebo group. However, there are some dif-
erences between our study and EVEREST. First, the EVEREST trial
ncluded only patients with heart failure with reduced ejection
raction (≤40%), and whether the results of this study would be
eplicated in other populations, including those patients with pre-
erved left ventricular ejection fraction, is unknown. Second, in the
VEREST trial, patients were randomized within 48 h of hospital-
zation. This means that tolvaptan might have been administered
fter enough diuresis was achieved by pre-administration of other
iuretics. Third, in EVEREST, serum creatinine was obtained only on
npatient day 1, day 7, and discharge. One study showed that WRF
n patients with heart failure occurred early in the course of the
ospitalization [35], and this might lead to underestimation of the
ncidence of WRF. Last, we included only patients who  were scored
s high-risk patients for WRF, and this difference in patients’ char-
cteristics may  have inﬂuenced the result that incidence of WRF
as lower in patients who were treated with tolvaptan.
imitations
Although our study was prospective, patients were not ran-
omized. This caused signiﬁcant differences in some baseline
haracteristics between the two groups, including the renal func-
ion, and the conclusion of our study was not robust due to these
ifferences even though multivariate analysis was  performed.
oreover, this study was based on a small number of patients in a
ingle center. As a prospective observational study, whether using
olvaptan or not for patients with heart failure was at the discretion
f the treating physician. We  did not evaluate diastolic function by
chocardiography because the study population included consid-
rable numbers of patients with atrial ﬁbrillation. Finally, because
o continue or discontinue the tolvaptan was decided by attending
hysician, the middle- to long-term outcome was not compared
etween the tolvaptan group and conventional therapy group.
onclusionsIn patients with ADHF, tolvaptan may  increase the urine output
ithout adverse effects, including WRF  in a high-risk population
or WRF. Although this ﬁnding suggests the usefulness of tolvaptan
[iology 61 (2013) 169–174 173
for patients with heart failure and renal failure, a prospective
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